
Neurology Resident @UniSpitalBasel with an orientation in Stroke Medicine
Basel, Switzerland
Joined February 2022
- Tweets79
- Following215
- Followers63
- Likes320
Avramiotis S. Nikolaos, MD, MSc retweeted
TECNO trial: Intra-arterial Tenecteplase after incomplete thrombectomy is safe but doesn’t significantly improve reperfusion or outcomes vs standard care. More research needed to refine patient selection and treatment strategies in stroke care.
#ESOC2026 #VoiceOfStroke #Stroke
Avramiotis S. Nikolaos, MD, MSc retweeted
#MondayTip
#TRIDENT
💊One pill could change post-ICH care.
🧠Low-dose triple antihypertensive therapy ↓ recurrent stroke by 39% and improved BP control vs standard care
☝️Simpler regimens may beat therapeutic inertia
🔗doi.org/10.1056/nejmoa251504…
Avramiotis S. Nikolaos, MD, MSc retweeted
New analyses from the OCEANIC-STROKE trial show the FXIa inhibitor asundexian reduces both the risk and severity of recurrent ischemic stroke in patients with non-cardioembolic stroke or high-risk TIA 📊
@ESOstroke #VoiceOfStroke #Stroke #ESOC2026 #ClinicalTrials
Avramiotis S. Nikolaos, MD, MSc retweeted
HOPE trial at #ESOC2026 🚨
Tailoring systolic BP to recanalisation status after EVT improves 90-day outcomes in acute ischemic stroke.
Findings:
•mRS 0–2: 60.0% vs 46.7%.
•Hemorrhage: 22.3% vs 31.6%.
•Mortality: 15% both.
•Supports individualised BP post-thrombectomy.
Avramiotis S. Nikolaos, MD, MSc retweeted
🧊 The CHILL-ART trial shows that intra-arterial selective hypothermia during thrombectomy improves 90-day functional independence (54.7% vs 39.8%) without increasing safety risks.
There was no increase in haemorrhage or mortality.
@ESOstroke #ESOC2026 #StrokeTreatment
Avramiotis S. Nikolaos, MD, MSc retweeted
Presented at #SVIN25:
CREST-2: In high-grade asymptomatic carotid stenosis, addition of stenting to medical therapy led to a lower risk of stroke over a 4-year period. Endarterectomy did not lead to a significant benefit. Full results: nej.md/3LK9kst
Editorial: Managing Asymptomatic Carotid Stenosis nej.md/482XjG1
@svinsociety
Avramiotis S. Nikolaos, MD, MSc retweeted
CREST-2 is out. I had Gemini make an infographic—no errors!
Avramiotis S. Nikolaos, MD, MSc retweeted
Verdict is out!!!!! #CREST2 RESULTS FAVORING CAS!!!
Absolute risk difference = 3.2% (95% Cl, 0.6 to 5.9; P=0.016) Relative risk = 2.13 (95% Cl, 1.15 to 4.39)
Happening now at #SVIN25
@svinsociety
@MThrombectomy – at Doctor Phillips, FL
Avramiotis S. Nikolaos, MD, MSc retweeted
#STROKE: In a secondary analysis of ARCADIA, randomization to apixaban was associated with a lower risk of recurrent ischemic stroke than aspirin in patients with left ventricular systolic dysfunction. @MitchElkind @hoomankamel @ShadiYaghi2 #AHAJournals ahajrnls.org/42Qu1bM
Avramiotis S. Nikolaos, MD, MSc retweeted
🚨 Keynote Alert at #ESOC2025!
GOLDEN BRIDGE II shows AI-driven clinical decision support can improve stroke recurrence rates without safety hazards in acute ischemic stroke care.
📍22 May | Helsinki
👥 21,600+ patients, 77 hospitals
#Stroke #AI #ClinicalTrials
Avramiotis S. Nikolaos, MD, MSc retweeted
#ESOC2025
🧠Covert Brain Infarction
⬆️Increase risk of Stroke ~2x
📈More CBI, more risk
☝️Inform the patient
🚭Treat risk factors
@ErasmusMC
Avramiotis S. Nikolaos, MD, MSc retweeted
Presented at #ESOC2025: Tirofiban, an IV antiplatelet, given as an adjunct to IVT, improved the odds of excellent functional outcome in patients with AIS, at the cost of an increased risk of intracranial bleeding in the ASSET-IT trial
#VoiceOfStroke
Avramiotis S. Nikolaos, MD, MSc retweeted
New DISTAL Trial sub-analysis: Endovascular therapy boosted chances of saving at least 80% of affected brain tissue in medium distal vessel occlusion stroke. Preservation of ≥80% of at-risk brain tissue significantly improved outcomes. Tissue saved = better recovery
#ESOC2025
Avramiotis S. Nikolaos, MD, MSc retweeted
#ESOC2025
🏃🏻♀️ESCAPE MEVO sub analysis
👉🏻 prognosis by image 🧠
👉🏻EVT <12 hs not > good functional outcome
👉🏻 Good collateral status > benefit
👉🏻 ⏱️<180 min > benefit
Avramiotis S. Nikolaos, MD, MSc retweeted
Presented at #ESOC2025:
Among 550 patients with stroke due to large-vessel occlusion who had presented within 4.5 hours after onset, 90-day functional outcomes were better with intravenous tenecteplase before thrombectomy than with thrombectomy alone.
Read the full BRIDGE-TNK trial results: nej.md/3GTVKAk
@ESOstroke
Avramiotis S. Nikolaos, MD, MSc retweeted
#ESOC2025 | The OPTIMIST trial suggests low-intensity monitoring after IV thrombolysis in mild to moderate stroke can deliver comparable safety & outcomes to standard protocols—while easing ICU strain & improving patient experience
📍4922 patients | 114 hospitals | 8 countries
Avramiotis S. Nikolaos, MD, MSc retweeted
BRIDGE TNK trial presented at #ESOC2025 shows superior outcomes with IV Tenecteplase + thrombectomy vs thrombectomy alone in acute LVO stroke within 4.5h
🧠 Functional independence - mRS 0–2
🟦 52.9% with bridging vs 44.1% thrombectomy
🧾 Adjusted RR 1.18
#StrokeTreatment
Avramiotis S. Nikolaos, MD, MSc retweeted
#ESOC2025
✅ASSET-IT: early tirofiban after IVT
👉🏻>mRS 0-1 and 0-2 at 90 day in Tirofiban arm
👉🏻 = sICH and mortality al 90 days































